Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 7/2009

Open Access 01-07-2009

Total Pelvic Exenteration for Primary and Recurrent Malignancies

Authors: F. T. J. Ferenschild, M. Vermaas, C. Verhoef, A. C. Ansink, W. J. Kirkels, A. M. M. Eggermont, J. H. W. de Wilt

Published in: World Journal of Surgery | Issue 7/2009

Login to get access

Abstract

Introduction

Complete resection is the most important prognostic factor in surgery for pelvic tumors. In locally advanced and recurrent pelvic malignancies, radical margins are sometimes difficult to obtain because of close relation to or growth in adjacent organs/structures. Total pelvic exenteration (TPE) is an exenterative operation for these advanced tumors and involves en bloc resection of the rectum, bladder, and internal genital organs (prostate/seminal vesicles or uterus, ovaries and/or vagina).

Methods

Between 1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent endometrial carcinoma. Ten patients were treated with neoadjuvant chemotherapy and 66 patients with preoperative radiotherapy to induce down-staging. Eighteen patients received IORT because of an incomplete or marginal complete resection.

Results

The median follow-up was 43 (range, 1–196) months. Median duration of surgery was 448 (range, 300–670) minutes, median blood loss was 6,300 (range, 750–21,000) ml, and hospitalization was 17 (range, 4–65) days. Overall major and minor complication rates were 34% and 57%, respectively. The in-hospital mortality rate was 1%. A complete resection was possible in 75% of all patients, a microscopically incomplete resection (R1) in 16%, and a macroscopically incomplete resection (R2) in 9%. Five-year local control for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively. Overall survival after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45%.

Conclusions

Total pelvic exenteration is accompanied with considerable morbidity, but good local control and acceptable overall survival justifies the use of this extensive surgical technique in most patients, especially patients with primary locally advanced rectal cancer and recurrent cervical cancer.
Literature
1.
Ferenschild FT, Vermaas M, Nuyttens JJ et al (2006) Value of intraoperative radiotherapy in locally advanced rectal cancer. Dis Colon Rectum 49:1257–1265PubMedCrossRef
2.
Vermaas M, Ferenschild FT, Nuyttens JJ et al (2005) Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum 48:918–928PubMedCrossRef
3.
Vermaas M, Ferenschild FT, Verhoef C et al (2007) Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncol 33:452–458PubMedCrossRef
4.
Bricker EM (1950) Bladder substitution after pelvic evisceration. Surg Clin N Am 30:1511PubMed
5.
Kecmanovic DM, Pavlov MJ, Kovacevic PA, Sepetkovski AV, Ceranic MS, Stamenkovic AB (2003) Management of advanced pelvic cancer by exenteration. Eur J Surg Oncol 29:743–746PubMedCrossRef
6.
Lopes A, Poletto AH, Carvalho AL, Ribeiro EA, Granja NM, Rossi BM (2004) Pelvic exenteration and sphincter preservation in the treatment of soft tissue sarcomas. Eur J Surg Oncol 30:972–975PubMed
7.
de Wilt JH, van Leeuwen DH, Logmans A et al (2007) Pelvic exenteration for primary and recurrent gynaecological malignancies. Eur J Obstet Gynecol Reprod Biol 134:243–248PubMedCrossRef
8.
9.
Chen HS, Sheen-Chen SM (2001) Total pelvic exenteration for primary local advanced colorectal cancer. World J Surg 25:1546–1549PubMedCrossRef
10.
Law WL, Chu KW, Choi HK (2000) Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg 190:78–83PubMedCrossRef
11.
Saito N, Koda K, Takiguchi N et al (2003) Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg 20:192–200PubMedCrossRef
12.
Yamada K, Ishizawa T, Niwa K, Chuman Y, Aikou T (2002) Pelvic exenteration and sacral resection for locally advanced primary and recurrent rectal cancer. Dis Colon Rectum 45:1078–1084PubMedCrossRef
13.
Nuyttens JJ, Kolkman-Deurloo IK, Vermaas M et al (2004) High-dose-rate intraoperative radiotherapy for close or positive margins in patients with locally advanced or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 58:106–112PubMedCrossRef
14.
Wanebo HJ, Antoniuk P, Koness RJ et al (1999) Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum 42:1438–1448PubMedCrossRef
15.
Quirke P, Durdey P, Dixon MF, Williams NS (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2:996–999PubMedCrossRef
16.
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete obeservations. J Am Stat Assoc 53:457–481CrossRef
17.
Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220
18.
Sharma S, Odunsi K, Driscoll D, Lele S (2005) Pelvic exenterations for gynecological malignancies: twenty-year experience at Roswell Park Cancer Institute. Int J Gynecol Cancer 15:475–482PubMedCrossRef
19.
Berek JS, Howe C, Lagasse LD, Hacker NF (2005) Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 99:153–159PubMedCrossRef
20.
Goldberg JM, Piver MS, Hempling RE, Aiduk C, Blumenson L, Recio FO (1998) Improvements in pelvic exenteration: factors responsible for reducing morbidity and mortality. Ann Surg Oncol 5:399–406PubMedCrossRef
21.
22.
Roos EJ, Van Eijkeren MA, Boon TA, Heintz AP (2005) Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer. Int J Gynecol Cancer 15:624–629PubMedCrossRef
23.
Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP (1999) Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75:99–102PubMedCrossRef
24.
Lewis JJ, Leung D, Woodruff JM, Brennan MF (1998) Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 228:355–365PubMedCrossRef
25.
Moriya Y, Akasu T, Fujita S, Yamamoto S (2004) Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum 47:2047–2054PubMedCrossRef
26.
Jimenez RE, Shoup M, Cohen AM, Paty PB, Guillem J, Wong WD (2003) Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer. Dis Colon Rectum 46:1619–1625PubMedCrossRef
27.
Lopez MJ, Standiford SB, Skibba JL (1994) Total pelvic exenteration. A 50-year experience at the Ellis Fischel Cancer Center. Arch Surg 129:390–396PubMed
28.
Houvenaeghel G, Moutardier V, Karsenty G et al (2004) Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients. Gynecol Oncol 92(2):680–683PubMedCrossRef
29.
Mills RD, Studer UE (1999) Metabolic consequences of continent urinary diversion. J Urol 161:1057–1066PubMedCrossRef
30.
Karsenty G, Moutardier V, Lelong B et al (2005) Long-term follow-up of continent urinary diversion after pelvic exenteration for gynecologic malignancies. Gynecol Oncol 97:524–528PubMedCrossRef
Metadata
Title
Total Pelvic Exenteration for Primary and Recurrent Malignancies
Authors
F. T. J. Ferenschild
M. Vermaas
C. Verhoef
A. C. Ansink
W. J. Kirkels
A. M. M. Eggermont
J. H. W. de Wilt
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 7/2009
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-009-0066-7

Other articles of this Issue 7/2009

World Journal of Surgery 7/2009 Go to the issue

OriginalPaper

Randomized Clinical Trial of Laparoscopic Versus Open Repair of the Perforated Peptic Ulcer: The LAMA Trial

OriginalPaper

Operative Debridement of Pressure Ulcers

OriginalPaper

Effects of Early Oral Feeding on Surgical Outcomes and Recovery After Curative Surgery for Gastric Cancer: Pilot Study Results

OriginalPaper

Long-Term Quality of Life After Hepatic Resection: Health Is not Simply the Absence of Disease

OriginalPaper

Benefits Versus Risks: A Prospective Audit

EditorialNotes

The World Journal of Surgery Welcomes Associate Editor—Ronnie T. P. Poon